NeoPharm CO., LTD. (092730.KQ)

KRW 12830.0

(0.39%)

EBITDA Summary of NeoPharm CO., LTD.

NeoPharm CO., LTD.'s latest annual EBITDA in 2023 was 31.01 Billion KRW , up 17.06% from previous year.
NeoPharm CO., LTD.'s latest quarterly EBITDA in 2024 Q3 was 5.08 Billion KRW , down -25.91% from previous quarter.
NeoPharm CO., LTD. reported an annual EBITDA of 24.89 Billion KRW in 2022, down -3.68% from previous year.
NeoPharm CO., LTD. reported an annual EBITDA of 25.32 Billion KRW in 2021, up 2.3% from previous year.
NeoPharm CO., LTD. reported a quarterly EBITDA of 5.08 Billion KRW for 2024 Q3, down -25.91% from previous quarter.
NeoPharm CO., LTD. reported a quarterly EBITDA of 6.86 Billion KRW for 2024 Q2, down -8.57% from previous quarter.

Annual EBITDA Chart of NeoPharm CO., LTD. (2023 - 2006)

Historical Annual EBITDA of NeoPharm CO., LTD. (2023 - 2006)

Year	EBITDA	EBITDA Growth
2023	31.01 Billion KRW	17.06%
2022	24.89 Billion KRW	-3.68%
2021	25.32 Billion KRW	2.3%
2020	24.44 Billion KRW	-3.37%
2019	24.75 Billion KRW	20.84%
2018	20.62 Billion KRW	34.63%
2017	14.82 Billion KRW	41.81%
2016	10.27 Billion KRW	45.84%
2015	5.25 Billion KRW	0.0%
2014	4.65 Billion KRW	N/A
2013	2.93 Billion KRW	N/A
2012	1.34 Billion KRW	0.0%
2011	1.72 Billion KRW	N/A
2010	2.52 Billion KRW	N/A
2009	2.95 Billion KRW	N/A
2008	3.61 Billion KRW	N/A
2007	1.61 Billion KRW	N/A
2006	3.75 Billion KRW	N/A

Year	EBITDA	EBITDA Growth
2024 Q1	7.5 Billion KRW	-5.15%
2024 Q3	5.08 Billion KRW	-25.91%
2024 Q2	6.86 Billion KRW	-8.57%
2023 Q1	7.44 Billion KRW	16.03%
2023 Q4	7.35 Billion KRW	34.64%
2023 FY	- KRW	17.06%
2023 Q2	6.67 Billion KRW	-10.28%
2023 Q3	5.45 Billion KRW	-18.21%
2022 Q2	5.33 Billion KRW	-20.64%
2022 Q4	6.41 Billion KRW	41.48%
2022 FY	- KRW	-3.68%
2022 Q3	4.53 Billion KRW	-15.05%
2022 Q1	6.72 Billion KRW	2.57%
2021 Q4	6.55 Billion KRW	72.13%
2021 Q3	3.8 Billion KRW	-41.09%
2021 FY	- KRW	2.3%
2021 Q2	6.46 Billion KRW	-8.41%
2021 Q1	7.05 Billion KRW	1.67%
2020 Q2	5.76 Billion KRW	-13.53%
2020 FY	- KRW	-3.37%
2020 Q4	6.94 Billion KRW	72.49%
2020 Q1	6.66 Billion KRW	12.44%
2020 Q3	4.02 Billion KRW	-30.2%
2019 FY	- KRW	20.84%
2019 Q4	5.92 Billion KRW	10.81%
2019 Q1	6.57 Billion KRW	10.13%
2019 Q2	6.31 Billion KRW	-3.89%
2019 Q3	5.35 Billion KRW	-15.3%
2018 Q1	5.89 Billion KRW	48.54%
2018 FY	- KRW	34.63%
2018 Q3	3.66 Billion KRW	-18.16%
2018 Q2	4.47 Billion KRW	-24.02%
2018 Q4	5.96 Billion KRW	62.96%
2017 Q1	4.47 Billion KRW	132.28%
2017 FY	- KRW	41.81%
2017 Q2	3.7 Billion KRW	-17.17%
2017 Q3	2.71 Billion KRW	-26.83%
2017 Q4	3.96 Billion KRW	46.24%
2016 Q3	2.3 Billion KRW	-3.84%
2016 FY	- KRW	45.84%
2016 Q2	2.39 Billion KRW	-37.77%
2016 Q4	1.92 Billion KRW	-16.42%
2016 Q1	3.85 Billion KRW	110.83%
2015 Q2	1.32 Billion KRW	0.0%
2015 FY	- KRW	0.0%
2015 Q3	1.36 Billion KRW	3.15%
2015 Q4	1.82 Billion KRW	33.58%
2013 Q2	478.99 Million KRW	-59.8%
2013 Q1	1.19 Billion KRW	3798.82%
2013 Q3	-402.16 Million KRW	-183.96%
2012 Q4	30.56 Million KRW	0.0%
2012 FY	- KRW	0.0%

Peer EBITDA Comparison of NeoPharm CO., LTD.

Name	EBITDA	EBITDA Difference
Kolmar BNH Co., Ltd.	46.76 Billion KRW	33.686%